Insights

Alpha | Godrej Agrovet Ltd. – Equity Research Desk

May 18, 2026 . Equities Desk

Alpha . Equity Research

Godrej Agrovet Ltd. – Feed-to-Food Agri Business

Founded in 1991 and headquartered in Mumbai, Godrej Agrovet Limited is one of India’s leading integrated food and agri-business companies with a diversified presence across the agricultural value chain. The company operates across key segments including Animal Nutrition, Crop Care, Dairy, Food, and Oil Palm, and holds leadership positions in several categories, including being India’s largest producer of crude palm oil and a leading player in the animal feed industry. Through its joint venture with ACI Limited, the company also has a strong presence in Bangladesh’s animal nutrition market. Godrej Agrovet operates a widespread manufacturing network with over 60 production facilities across India.

Products and Services

The company operates across diversified agri and food businesses, catering to multiple segments of the agricultural value chain:

Animal Nutrition – Offers a wide range of animal feed products across cattle, poultry, and aqua feed segments, with a strong pan-India presence.
Oil Palm Business – India’s largest producer of crude palm oil, engaged in oil palm plantation development and processing.
Crop Care – Provides agrochemical and crop protection solutions catering to the entire crop lifecycle, including plant growth regulators, herbicides, insecticides, and fungicides.
Dairy Business – Markets milk and value-added dairy products under the Godrej Jersey brand.
Poultry & Processed Foods – Offers poultry products and ready-to-cook/snack products under the Real Good Chicken and Yummiez brands.
Astec LifeSciences – Engaged in the manufacturing of active ingredients, intermediates, and formulations for the agrochemical industry through Astec LifeSciences Limited.

Subsidiaries – As of FY25, the company has 7 subsidiaries and 1 joint venture.

Investment Rationale

Animal Nutrition business witnessing strong volume-led growth with improving profitability – The company’s Animal Nutrition segment, contributing nearly 46% of overall revenues, continued to deliver strong broad-based growth, with volumes rising 12% in FY26 and further accelerating to 15% YoY in Q4FY26. Growth was led by the cattle feed segment, where volumes increased 24% YoY during the quarter, supported by rising demand and deeper market penetration. The company’s expansion beyond its traditionally strong Western India markets into Central and Eastern India has started yielding tangible results, providing incremental growth avenues. Additionally, the increasing contribution from premium and value-added products such as Dhanalaxmi G and Bypro Plus aided both realisations and product mix improvement. Operational efficiencies and better mix led to EBIT margin expansion to 10.4% in Q4FY26 versus 5.7% in the corresponding period last year. Segment EBIT grew 20% YoY during FY26, reflecting the sustainability of earnings improvement driven by geographic expansion, premiumisation, and strong execution.

Improving capital efficiency and recovery across businesses to support earnings growth – The company has witnessed a sharp improvement in capital efficiency over the last three years, with ROCE improving from 13% in FY24 to 16% in FY25 and further to 20% in FY26. The improvement has been driven largely by better working capital management, as net working capital days reduced significantly from 45 days in FY24 to 25 days in FY26, releasing nearly ₹486 crore of capital. On the profitability front, PBT grew 17% YoY to ₹569 crore in FY26 despite revenue growth of 9%, indicating meaningful margin expansion and improved operational efficiency. Notably, this performance came despite weakness in certain segments, including lower crop care margins, pressure in the dairy business, and revenue decline in Godrej Foods. Looking ahead, the company appears well-positioned for a broader earnings recovery in FY27. Astec LifeSciences has improved from EBITDA losses to breakeven and is targeting healthy revenue growth, while the crop care business is expected to recover from Q2FY27 supported by channel inventory normalisation and scaling up of new products such as Takai and Ashitaka. Additionally, easing milk procurement cost pressures and improving branded product mix in the Foods segment are likely to support margin recovery. Management has guided for early double-digit revenue growth along with mid-teen PBT growth in FY27, which could further strengthen profitability as multiple business segments contribute simultaneously.

Q4FY26 – During the quarter, the company generated its highest ever quarterly revenue of ₹2,333 crore, an increase of 9.3% compared to the ₹2,134 crore of Q4FY25. EBITDA increased from ₹160 crore of Q4FY25 to ₹173 crore of Q4FY26, a growth of 8.5%. The company reported net profit of ₹74 crore, an increase by 11.3% YoY compared to ₹66 crore of the corresponding period of the previous year.

FY26 – During the FY, the company generated revenue of ₹10,233 crore, an increase of 9.1% compared to the FY25 revenue. EBITDA is at Rs.936 crore, up by 10.8% YoY. The company reported net profit of Rs.440 crore, an increase of 13.9% YoY.

Financial Performance – The 3-year revenue and net profit CAGR stands at 3% and 26% respectively between FY24-26. The company has a healthy capital structure with a debt-to-equity ratio of 0.77. Average 3-year ROE and ROCE is around 18% and 17% for FY24-26 period.

Industry

India’s agriculture and allied sector is a structural pillar of the economy, contributing ~18% of GDP and employing nearly half the workforce. The country holds dominant global positions – largest cattle herd, largest area under wheat, rice and cotton, and the world’s top producer of milk, pulses and spices. The sector is projected to sustain ~4% growth over the next decade, supported by rising domestic food demand, increasing mechanisation and technology adoption, and a strengthening export pipeline. Within agriculture, livestock has emerged as the faster-growing sub-sector, expanding at a 7.1% CAGR over the past decade versus ~3.5% for crops, now contributing ~16% of farmers’ income – a structural shift that is reshaping how capital and policy attention is allocated across the sector. Taken together, India’s inherent agricultural scale, favourable demographics, and an increasingly organised agribusiness landscape create a durable long-term growth backdrop for the sector.

Growth Drivers

The Union Cabinet approved the Prime Minister Dhan-Dhaanya Krishi Yojana (PMDDKY) worth ₹24,000 crore (US$ 2.79 billion) from FY26 to support the sector.
The Department of Agriculture and Farmers’ Welfare budget has grown from ₹21,934 crore in FY2013-14 to approximately ₹1,30,692 crore in FY2026-27, reflecting a ~6x increase in government agricultural spending over the past decade.
The Department of Animal Husbandry and Dairying received its highest-ever budget allocation of ₹6,153 crore in FY2026-27, a 27% jump year-on-year.

Peer Analysis

Competitors: Avanti Feeds Ltd, Mukka Proteins Ltd, etc.

In comparison to the above competitors, Godrej Agrovet is a reasonably valued stock with healthy returns on the capital employed and stable growth in sales.

Outlook

Godrej Agrovet enters FY27 with management guiding early double-digit revenue growth and mid-teens PBT growth. The animal nutrition business, which drove the FY26 story, is sustaining momentum with broad-based volume growth and geographic expansion into Central and East India still in early stages. Oil palm adds another volume growth lever with early double-digit expansion expected in FY27. On capital allocation, the company has guided ₹400 crore in total capex with ~₹100-125 crore cash surplus remaining, and a long-term capex framework of ~₹350 crore annually with 75-80% directed toward growth. With working capital days compressed to 25, ROCE at 20% and improving, and drag businesses like Astec and Godrej Foods now turning around, FY27 is set up as the first year where most segments contribute simultaneously.

Valuations

We expect Godrej Agrovet to continue its growth momentum underpinned by accelerating volume momentum in branded cattle feed, an improving mix in value-added poultry and dairy, and an expected recovery in crop protection and Astec LifeSciences in FY27. We recommend a BUY rating in the stock with the target price (TP) of ₹683, 26x FY28E EPS. We also encourage maintaining a stop-loss at 20% from the entry price to manage potential downside risk effectively.

SWOT Analysis

Strength	Weakness
Leadership position across animal feed and crude palm oil, with over 1 million tonnes of annual feed sales and the largest domestic CPO producer. Innovations in crop protection business. Strong R&D backbone through NGCARD and dedicated aqua feed and crop protection research centres, supporting consistent new product launches and premiumisation.	Businesses are subject to seasonal variations – unseasonal rains in Q1 FY26 disrupted dairy demand and heavy rains in Q2 FY26 impacted crop protection volumes. Revenue growth is predominantly volume-driven with limited pricing power in a price-sensitive consumer segment, constraining the ability to fully pass on input cost increases.
Opportunities	Threats
Accelerating volume growth in animal feed, particularly branded cattle feed, with geographic expansion into Central and East India still in early stages. Increasing market share across existing verticals through premiumisation – new value-added products like Dhanalaxmi G and Bypro Plus in feed, and branded salience above 80% in Godrej Foods. Recovery potential in crop protection and Astec LifeSciences in FY27, as channel inventory normalises, new multi-crop products scale up, and CDMO demand strengthens – segments that were a drag in FY26.	Raw material price volatility – elevated milk procurement costs compressed dairy EBITDA margins by FY26, illustrating the sensitivity of margins to input cost movements. Unfavourable weather patterns remain a structural risk – adverse monsoons, unseasonal rains, and cyclones have historically impacted crop protection volumes, dairy demand, and oil palm FFB arrivals.

Disclaimer: Investments in the securities market are subject to market risks, read all related documents carefully before investing. Securities quoted here are exemplary, not recommendatory. Please consult your financial advisor before investing. Please note that we do not guarantee any assured returns for the securities quoted here.

Research disclaimer: Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.

For more details, please read the disclaimer.